Atlas Trials

TG Therapeutics, Inc.

40 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch TG Therapeutics, Inc.

RecordFirmDate
Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel (NCT07577583)TG Therapeutics, Inc.2027-05-01
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG) (NCT07673744)TG Therapeutics, Inc.2026-07-30
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia (NCT07680946)TG Therapeutics, Inc.2026-07-03
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (NCT07220252)TG Therapeutics, Inc.2026-07-01
A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS) (NCT07503873)TG Therapeutics, Inc.2026-04-01
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) (NCT07211633)TG Therapeutics, Inc.2025-07-09
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders (NCT06680037)TG Therapeutics, Inc.2025-05-06
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) (NCT06433752)TG Therapeutics, Inc.2024-07-22
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS) (NCT06433765)TG Therapeutics, Inc.2024-06-01
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk (NCT06143514)TG Therapeutics, Inc.2024-03-26
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab (NCT05877963)TG Therapeutics, Inc.2023-06-13
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia (NCT04806035)TG Therapeutics, Inc.2021-04-28
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis (NCT04130997)TG Therapeutics, Inc.2019-11-18
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax (NCT04016805)TG Therapeutics, Inc.2019-08-05
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma (NCT03828448)TG Therapeutics, Inc.2019-07-10
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) (NCT03801525)TG Therapeutics, Inc.2019-05-16
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma (NCT03778073)TG Therapeutics, Inc.2019-04-17
Study of TG-1801 in Subjects With B-Cell Lymphoma (NCT03804996)TG Therapeutics, Inc.2019-03-05
Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies (NCT03671590)TG Therapeutics, Inc.2018-09-10
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL (NCT03379051)TG Therapeutics, Inc.2018-03-27
Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma (NCT03364231)TG Therapeutics, Inc.2017-11-30
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) (NCT03277261)TG Therapeutics, Inc.2017-09-19

Track TG Therapeutics, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.